Z17.22 — Progesterone receptor negative status
Is Z17.22 billable?
Yes — Z17.22 is billable for FY2027. Z17.22 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. Z17.22 may be submitted for encounters from October 1, 2026 through September 30, 2027.
Z17.22 at a glance
| Code | Z17.22 |
|---|---|
| Description | Progesterone receptor negative status |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to Z17.22?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name Z17.22 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does Z17.22 group to?
Z17.22 sits in MDC 23 and helps define the logic of 2 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 947Signs and Symptoms with MCCmedical
- 948Signs and Symptoms without MCCmedical
How is Z17.22 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to Z17.22. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Status › progesterone receptor › negative (post)
Inclusion terms
Alternative wording in documentation that is classified to Z17.22.
- PR-
Code first — inherited from Z17
The underlying condition below must be sequenced before Z17.22. Z17.22 describes a manifestation and cannot be the principal or first-listed diagnosis.
How long has Z17.22 existed?
Z17.22 first appears in FY2025.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.